Phio Pharmaceuticals
PHIO
7 hedge funds and large institutions have $287K invested in Phio Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 4 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0% less ownership
Funds ownership: 0% → 0% (-0%)
30% less funds holding
Funds holding: 10 → 7 (-3)
62% less capital invested
Capital invested by funds: $748K → $287K (-$461K)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SG Americas Securities
New York
|
+$75.3K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$18.8K |
| 3 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
+$9.41K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.41K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$325K |
| 2 |
DS
DRW Securities
Chicago,
Illinois
|
-$37K |
| 3 |
VF
Virtu Financial
New York
|
-$23K |
| 4 |
FAAS
First Allied Advisory Services
San Diego,
California
|
-$22K |
| 5 |
IP
Intellectus Partners
San Francisco,
California
|
-$9.41K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
SG Americas Securities
New York
| $192K | +$75.3K | +8 | +40% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $35K | +$9.41K | +1 | +25% |
|
|
TSS
3
Two Sigma Securities
New York
| $16K | +$18.8K | +2 | New |
|
|
EDRH
4
Edmond de Rothschild Holding
Chambesy,
Switzerland
| $13K | +$9.41K | +1 | +100% |
|
5
HighTower Advisors
Chicago,
Illinois
| $12K | – | – | – |
|
|
IP
6
Intellectus Partners
San Francisco,
California
| $9K | -$9.41K | -1 | -50% |
|
7
Morgan Stanley
New York
| $7K | – | – | – |
|
8
Bank of America
Charlotte,
North Carolina
| $1K | – | – | – |
|
9
BlackRock
New York
| $1K | – | – | – |
|
10
UBS Group
Zurich,
Switzerland
| $1K | – | – | – |
|
|
BDWM
11
Brewin Dolphin Wealth Management
Conskleagh, Dublin,
Ireland
| $1 | – | – | – |
|
|
SM
12
Sabby Management
Miami Beach,
Florida
| – | -$325K | -28 | Closed |
|
|
DS
13
DRW Securities
Chicago,
Illinois
| – | -$37K | -3 | Closed |
|
|
FAAS
14
First Allied Advisory Services
San Diego,
California
| – | -$22K | -2 | Closed |
|
|
VF
15
Virtu Financial
New York
| – | -$23K | -2 | Closed |
|
PHIO Hedge Fund Activity: Q3 2018 in Review
7 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q3 2018, worth a combined $287K — down 62% from $748K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of PHIO and 1 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 3 added.
The largest buyer was SG Americas Securities, adding an estimated $75.3K. The largest seller was Sabby Management, exiting entirely with an estimated $325K sold.
- 7 institutional investors held Phio Pharmaceuticals (PHIO) as of Q3 2018, down from 10 in Q2 2018.
- Funds reported $287K of Phio Pharmaceuticals stock for Q3 2018, down 62% quarter-over-quarter.
- 1 fund opened new Phio Pharmaceuticals positions in Q3 2018 and 4 closed out, a net change of -3 holders.
- The largest Phio Pharmaceuticals buyer in Q3 2018 was SG Americas Securities, an estimated $75.3K added.
- The largest Phio Pharmaceuticals seller in Q3 2018 was Sabby Management, an estimated $325K sold.
Based on aggregated 13F filings for Q3 2018.